Myopia Control Glasses: New 2-Year Study Shows They Slow Progression
A New U.S. Study Changes the Conversation About Children’s Myopia
For generations, the standard response when a child became more nearsighted was straightforward: update the prescription and make a stronger pair of glasses. The child could see clearly again, everyone moved on, and the process repeated when the prescription changed the next year.
Today, that approach is increasingly difficult to justify for a child whose myopia is progressing. We now have multiple evidence-based options designed not just to correct blurry distance vision, but to slow the progression of myopia itself. A new randomized clinical trial published in JAMA Ophthalmology adds important U.S. evidence for one of those options: specially designed myopia-control spectacle lenses.
The study is especially relevant for parents because it compared myopia-control glasses directly with conventional single-vision glasses over two full years in U.S. children. The results were clear: the specialized lenses significantly slowed both prescription change and eye growth.
What the New JAMA Ophthalmology Study Found
The randomized clinical trial enrolled 159 children ages 6 to 12 at nine U.S. investigational sites. Children were assigned either highly aspherical lenslet, or HAL, spectacle lenses designed for myopia control, or conventional single-vision spectacle lenses. Researchers followed the children for 24 months and measured two of the most important markers in myopia management: change in prescription and axial length, which is the front-to-back length of the eye.
After two years, children wearing the myopia-control lenses had an average myopia progression of -0.25 diopters compared with -0.90 diopters in the single-vision group. That represents a 71% relative reduction in myopia progression. Axial elongation was also lower: 0.21 mm with the myopia-control lenses compared with 0.45 mm with conventional lenses, a 53% relative reduction.
Visual acuity was equivalent between the two groups, and no serious or lens-related ocular adverse events were reported. In other words, the children still saw clearly through the glasses while gaining the additional benefit of substantially slower myopia progression.
The Biggest Benefit Was Seen in Younger Children
One of the most important findings was the strong treatment effect in children ages 6 to 8. In this younger group, the researchers reported an 87% myopia-control effect and more than a 1.00 diopter reduction in progression compared with the control group.
That matters because younger children with myopia often have more years of eye growth ahead of them. A child who becomes nearsighted at age 7 has much more time for myopia to progress than a child who first becomes nearsighted at 14. Earlier onset is also associated with a greater likelihood of developing higher levels of myopia later in life.
The practical takeaway for parents is simple: early intervention matters.
Waiting several years to see how much a young child’s prescription changes can mean losing valuable time when myopia may be most responsive to treatment.
Why Regular Single-Vision Glasses Are No Longer Enough
Regular glasses do an excellent job of one thing: correcting blurry vision. They help a nearsighted child see the board, recognize faces across the room, and function comfortably at school and at home. What they generally do not do is address the underlying progression of myopia.
That distinction is important. Myopia usually worsens because the eye is growing too long from front to back. A stronger prescription restores clear vision, but it does not necessarily slow that eye growth. Myopia management is different because the goal is to reduce how quickly the prescription and axial length change over time.
For a child with progressive myopia, simply prescribing another pair of standard single-vision glasses without discussing evidence-based myopia-management options is becoming harder to defend. Parents should expect a conversation not only about how clearly their child sees today, but also about what can be done to reduce future progression.
This Is Not the First Study Showing Myopia Spectacles Work
The new U.S. trial is important, but it does not stand alone. Earlier randomized studies in Asia also found that spectacle lenses using highly aspherical lenslet technology significantly slowed myopia progression and axial elongation compared with standard single-vision lenses. Longer-term follow-up has shown that the treatment effect can be sustained over several years.
What is changing now is the strength and geographic relevance of the evidence. We have data from multiple studies, different populations, and longer follow-up periods all pointing in the same direction: specially designed myopia-control spectacle lenses can safely and meaningfully slow progression in children.
Myopia Control Is About More Than a Pair of Glasses
Myopia-control spectacles are an important option, particularly for families who prefer glasses or for younger children who may not be ready for contact lenses. But they are only one part of modern myopia management. Other evidence-based options can include specially designed soft contact lenses, orthokeratology lenses worn overnight, and low-dose atropine eye drops.
The right treatment depends on the child. Age, prescription, rate of progression, axial length, lifestyle, maturity, sports participation, family history, and parent preferences can all influence the best approach. Some children may do well with one therapy, while others may benefit from a different option or a change in treatment over time.
That is why comprehensive myopia management involves more than selecting a product. It requires measuring the child’s eyes, choosing an appropriate treatment, monitoring whether it is working, and adjusting the plan when needed.
How We Approach Childhood Myopia
Brighter Outlook Vision focus specifically on myopia management for children. We evaluate risk, measure eye growth, select individualized treatment, and monitor progress over time.
A myopia management evaluation includes axial length measurement, review of prescription history and family history, assessment of age and lifestyle risk factors, discussion of multiple myopia-control options, and ongoing follow-up to determine whether treatment is achieving the desired result.
This measurement-based approach matters because two children with the same prescription may not be progressing at the same rate. The goal is not simply to help a child see clearly today. It is to understand how the eyes are changing and do everything evidence-based medicine allows us to do to slow that change.
What Parents Should Ask Their Eye Doctor
If your child is nearsighted, especially if the prescription has increased over the past year, consider asking:
- Have you measured my child’s axial length?
- Is my child’s myopia progressing?
- What myopia-control options are appropriate for my child’s age? Ortho-K, atropine drops, lenses, contacts?
- How will we know whether the treatment is working?
- How often should my child be monitored?
If the only recommendation is to increase the strength of a conventional prescription and come back in a year, it is reasonable to ask specifically about myopia management or seek an evaluation from a doctor who routinely provides it.
The Bottom Line
The new JAMA Ophthalmology study gives parents another reason to think differently about childhood myopia. In a two-year U.S. randomized clinical trial, specialized myopia-control spectacle lenses substantially reduced both prescription progression and axial eye growth compared with regular single-vision glasses. Younger children ages 6 to 8 experienced the greatest benefit.
For children whose myopia is progressing, clear vision should no longer be the only goal. The standard should be clear vision plus a plan to slow progression whenever appropriate.
If your child’s prescription is getting stronger, schedule a comprehensive myopia evaluation with us as soon as possible. The earlier we understand how quickly the eyes are changing, the more opportunity we may have to protect long-term vision.
Source Notes
Primary study: Shen J, Hunt C, Young G, Drobe B. Spectacle Lenses With Highly Aspherical Lenslets for Myopia Control: A Randomized Clinical Trial. JAMA Ophthalmology. Published online August 20, 2026. doi:10.1001/jamaophthalmol.2026.3288. Study included 159 U.S. children ages 6-12 and compared highly aspherical lenslet spectacle lenses with conventional single-vision lenses over 24 months. Earlier supporting evidence includes a 2022 JAMA Ophthalmology randomized clinical trial of aspherical lenslet spectacle designs over two years.
